Results 181 to 190 of about 65,156 (262)

Anti-IgE Treatment for Disorders Other Than Asthma. [PDF]

Front Med (Lausanne), 2017
Stokes J.
europepmc   +1 more source

Chinese Position Paper on Biologic Therapy for Allergic Rhinitis

Allergy, EarlyView.
ABSTRACT Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to ...
Yuan Zhang, Jingyun Li, Xian Li, Menglin Wang, Xiangli Yang, Li Shi, Zhiwei Cao, Yan Feng, Weiwei Liu, Zhendong Xu, Ruixia Ma, Xiaoping Gao, Wen Liu, Jinmei Xue, Xiaoyong Ren, Xuezhong Li, Xicheng Song, Yi Yang, Fang Quan, Lei Cheng, Weihong Jiang, Huabin Li, Jian Li, Huanhai Liu, Jianfeng Liu, Zheng Liu, Wei Lv, Qianhui Qiu, Xiangdong Wang, Yu Xu, Yuanteng Xu, Qintai Yang, Yucheng Yang, Jing Ye, Hongmeng Yu, Dongdong Zhu, Chengshuo Wang, Luo Zhang   +37 more
wiley   +1 more source

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology, EarlyView.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J. Cooper, John Gordon, Catherine A. Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews, Nicholas M. Barnes   +10 more
wiley   +1 more source

Severe asthma: anti-IgE or anti-IL-5? [PDF]

Eur Clin Respir J, 2016
Papathanassiou E, Loukides S, Bakakos P.
europepmc   +1 more source

Protectin D1 and maresin 1 attenuate airway hyperreactivity induced by IL‐13 in human isolated small bronchi

British Journal of Pharmacology, EarlyView.
Background and Purpose Interleukin (IL)‐13 is implicated in airway hyperreactivity (AHR), a key feature of asthma. We explored the potential anti‐AHR activity of selected specialised pro‐resolving mediators (SPMs) in IL‐13‐induced AHR models, using human bronchial smooth muscle cells (BSMCs) and human isolated bronchi.
Willem Abma, Sven‐Erik Dahlén, Craig E. Wheelock, Mikael Adner, Mamdoh Al‐Amerie, Erik Sachs, Kasra Vali Jalali, Leonardo De Maria, Henric Olsson, Jesper Säfholm   +9 more
wiley   +1 more source

Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus. [PDF]

Arthritis Rheumatol, 2019
Hasni S, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Joyal E, Fike A, Manna Z, Auh S, Shi Y, Chan D, Carlucci P, Biehl A, Dema B, Charles N, Balow JE, Waldman M, Siegel RM, Kaplan MJ, Rivera J.   +19 more
europepmc   +1 more source

Safety, tolerability, pharmacokinetics and pharmacodynamics of the spleen tyrosine kinase inhibitor BI 894416 in healthy volunteers and patients with asthma

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Spleen tyrosine kinase (SYK) has broad biological functions in inflammation and immunity. The orally administered SYK inhibitor BI 894416 was investigated in a single‐rising‐dose Phase I study in healthy volunteers and in a combined single‐ and multiple‐rising‐dose Phase Ib study in patients with mild asthma ...
Saskia Carstensen‐Aurèche, Tobias Litzenburger, Dorothy De Sousa, Reinhard Sailer, Ewald Benediktus, Denis Delic, Fabian Müller, Meike Müller, Jens M. Hohlfeld   +8 more
wiley   +1 more source

Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody. [PDF]

Sci Rep, 2018
Chen JB, Ramadani F, Pang MOY, Beavil RL, Holdom MD, Mitropoulou AN, Beavil AJ, Gould HJ, Chang TW, Sutton BJ, McDonnell JM, Davies AM.   +11 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases. [PDF]

Curr Respir Med Rev, 2017
Licari A, Castagnoli R, Panfili E, Marseglia A, Brambilla I, Marseglia GL.   +5 more
europepmc   +1 more source